• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

HDAC11 is related to breast cancer prognosis and inhibits invasion and proliferation of breast cancer cells
CONCLUSION: In conclusion, this study found that HDAC11 expression is positively correlated with the overall survival rate of patients. HDAC11 can inhibit the invasion and proliferation of breast cancer cells to a certain extent and can be used as a good prognosis marker.PMID:37559686 | PMC:PMC10408431
Source: Clinical Breast Cancer - August 10, 2023 Category: Cancer & Oncology Authors: Hao Zhao Xu-Ming Zhang Sheng Xiao Zhen-Ru Wu Yu-Jun Shi Ming-Jun Xie Source Type: research

The prognostic value of DAAM2 in lower grade glioma, liver cancer, and breast cancer
CONCLUSION: DAAM2 had a specific value in foretelling the prognosis of LGG, LIHC, and BRCA. High expression level of DAAM2 has longer survival rates in LGG and LIHC. The knockdown of DAAM2 retards the proliferation, invasion, and migration of BRCA cells. This study provides a novel sight of DAAM2 into the exploration of a potential biomarker in pan-cancer.PMID:36790676 | DOI:10.1007/s12094-023-03111-x
Source: Clinical Breast Cancer - February 15, 2023 Category: Cancer & Oncology Authors: Zeying Li Xiao Wei Yichao Zhu Source Type: research

Down-regulation of BRMS1 by DNA hypermethylation and its association with metastatic progression in triple-negative breast cancer.
In this study, we found that BRMS1 was down-regulation in breast cancer cell lines and primary TNBC, while decreased expression of BRMS1 mRNA was significantly associated with lymph node metastasis. And this down-regulation was found to be in accordance with aberrant methylation of the gene. Hypermethylation of the gene was observed in 53.4% (62/116) of the TNBC primary breast carcinomas, while it was found in only 24.1% (28/116) of the corresponding nonmalignant tissues. In addition, BRMS1 expression was restored in MDA-MB-231 after treatment with the demethylating agent, 5-aza-2-deoxycytidine (5-Aza-dC), and demethylatio...
Source: Clinical Breast Cancer - December 2, 2015 Category: Cancer & Oncology Authors: Kong B, Lv ZD, Wang Y, Jin LY, Ding L, Yang ZC Tags: Int J Clin Exp Pathol Source Type: research